Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Self-assembling dipeptide antibacterial nanostructures with membrane disrupting activity.

Schnaider L, Brahmachari S, Schmidt NW, Mensa B, Shaham-Niv S, Bychenko D, Adler-Abramovich L, Shimon LJW, Kolusheva S, DeGrado WF, Gazit E.

Nat Commun. 2017 Nov 8;8(1):1365. doi: 10.1038/s41467-017-01447-x.

2.

Periodontitis, Microbiomes and their Role in Alzheimer's Disease.

Pritchard AB, Crean S, Olsen I, Singhrao SK.

Front Aging Neurosci. 2017 Oct 24;9:336. doi: 10.3389/fnagi.2017.00336. eCollection 2017.

3.

UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease.

Wang CY, Wang PN, Chiu MJ, Finstad CL, Lin F, Lynn S, Tai YH, De Fang X, Zhao K, Hung CH, Tseng Y, Peng WJ, Wang J, Yu CC, Kuo BS, Frohna PA.

Alzheimers Dement (N Y). 2017 Apr 14;3(2):262-272. doi: 10.1016/j.trci.2017.03.005. eCollection 2017 Jun.

4.

Hyperhomocysteinemia, Suppressed Immunity, and Altered Oxidative Metabolism Caused by Pathogenic Microbes in Atherosclerosis and Dementia.

McCully KS.

Front Aging Neurosci. 2017 Oct 6;9:324. doi: 10.3389/fnagi.2017.00324. eCollection 2017. Review.

5.

Aβ Peptide Originated from Platelets Promises New Strategy in Anti-Alzheimer's Drug Development.

Inyushin MY, Sanabria P, Rojas L, Kucheryavykh Y, Kucheryavykh L.

Biomed Res Int. 2017;2017:3948360. doi: 10.1155/2017/3948360. Epub 2017 Sep 5. Review.

6.

A Toxic Conformer of Aβ42 with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease.

Izuo N, Kasahara C, Murakami K, Kume T, Maeda M, Irie K, Yokote K, Shimizu T.

Sci Rep. 2017 Sep 18;7(1):11811. doi: 10.1038/s41598-017-11671-6.

7.

The hypothesis that Helicobacter pylori predisposes to Alzheimer's disease is biologically plausible.

Felice C, Federico C, Andrea F, Riccardo AC, Walter S, Domenico I, Chiara M, Rosanna C.

Sci Rep. 2017 Aug 10;7(1):7817. doi: 10.1038/s41598-017-07532-x.

8.

Changes in lipid membranes may trigger amyloid toxicity in Alzheimer's disease.

Drolle E, Negoda A, Hammond K, Pavlov E, Leonenko Z.

PLoS One. 2017 Aug 2;12(8):e0182194. doi: 10.1371/journal.pone.0182194. eCollection 2017.

9.

Differential Phenotypes of Myeloid-Derived Suppressor and T Regulatory Cells and Cytokine Levels in Amnestic Mild Cognitive Impairment Subjects Compared to Mild Alzheimer Diseased Patients.

Le Page A, Garneau H, Dupuis G, Frost EH, Larbi A, Witkowski JM, Pawelec G, Fülöp T.

Front Immunol. 2017 Jul 7;8:783. doi: 10.3389/fimmu.2017.00783. eCollection 2017.

10.

Evidence that the Human Innate Immune Peptide LL-37 may be a Binding Partner of Amyloid-β and Inhibitor of Fibril Assembly.

De Lorenzi E, Chiari M, Colombo R, Cretich M, Sola L, Vanna R, Gagni P, Bisceglia F, Morasso C, Lin JS, Lee M, McGeer PL, Barron AE.

J Alzheimers Dis. 2017;59(4):1213-1226. doi: 10.3233/JAD-170223.

11.

Polymicrobial Infections In Brain Tissue From Alzheimer's Disease Patients.

Pisa D, Alonso R, Fernández-Fernández AM, Rábano A, Carrasco L.

Sci Rep. 2017 Jul 17;7(1):5559. doi: 10.1038/s41598-017-05903-y.

12.

Amyloid beta: structure, biology and structure-based therapeutic development.

Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE.

Acta Pharmacol Sin. 2017 Sep;38(9):1205-1235. doi: 10.1038/aps.2017.28. Epub 2017 Jul 17. Review.

PMID:
28713158
13.

16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer's Post-Mortem Brain.

Emery DC, Shoemark DK, Batstone TE, Waterfall CM, Coghill JA, Cerajewska TL, Davies M, West NX, Allen SJ.

Front Aging Neurosci. 2017 Jun 20;9:195. doi: 10.3389/fnagi.2017.00195. eCollection 2017.

14.

The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease.

Drew SC.

Front Neurosci. 2017 Jun 2;11:317. doi: 10.3389/fnins.2017.00317. eCollection 2017. Review.

15.

A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease.

Wang SW, Liu DQ, Zhang LX, Ji M, Zhang YX, Dong QX, Liu SY, Xie XX, Liu RT.

Alzheimers Res Ther. 2017 Jun 7;9(1):41. doi: 10.1186/s13195-017-0267-5.

16.

Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration.

Wilkins HM, Weidling IW, Ji Y, Swerdlow RH.

Front Immunol. 2017 Apr 26;8:508. doi: 10.3389/fimmu.2017.00508. eCollection 2017. Review.

17.

Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects.

Tomlinson JJ, Shutinoski B, Dong L, Meng F, Elleithy D, Lengacher NA, Nguyen AP, Cron GO, Jiang Q, Roberson ED, Nussbaum RL, Majbour NK, El-Agnaf OM, Bennett SA, Lagace DC, Woulfe JM, Sad S, Brown EG, Schlossmacher MG.

J Neural Transm (Vienna). 2017 Jun;124(6):721-738. doi: 10.1007/s00702-017-1726-7. Epub 2017 May 5.

18.

Aggregation of thrombin-derived C-terminal fragments as a previously undisclosed host defense mechanism.

Petrlova J, Hansen FC, van der Plas MJA, Huber RG, Mörgelin M, Malmsten M, Bond PJ, Schmidtchen A.

Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4213-E4222. doi: 10.1073/pnas.1619609114. Epub 2017 May 4.

19.

Microbial Immuno-Communication in Neurodegenerative Diseases.

Main BS, Minter MR.

Front Neurosci. 2017 Mar 23;11:151. doi: 10.3389/fnins.2017.00151. eCollection 2017. Review.

20.

Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis.

Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J.

Alzheimers Dement (Amst). 2017 Feb 9;7:69-87. doi: 10.1016/j.dadm.2017.01.005. eCollection 2017. Review.

Supplemental Content

Support Center